B-cell Malignancy clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
open to eligible people ages 18 years and up
Study consists of two main parts to explore BGB-16673 recommended dosing, a Part 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a part 2 (dose expansion cohorts)
at UCLA UCSD
Last updated: